Researchers at the Minneapolis Heart Institute recently published a study that suggests that the coronary artery calcium (CAC) level is a reliable indicator to differentiate candidates who would benefit from aspirin, from those who would not. The study shows participants with a CAC score of greater than or equal to 100 benefitted most from aspirin therapy, while participants with lower scores did not necessarily do so.

According to lead author of the study Dr. Michael D. Miedema, the recommended approach for individuals with known cardiovascular disease (CVD) is a daily dose of aspirin, but for those without known CVD, the best approach still remains unclear. He further identified a problem with this approach, commenting on the fact that only treating high-risk individuals would mean leaving out a substantial number of patients who eventually suffer from heart attacks.

“Approximately 50 percent of middle-aged men and women have a CAC score of zero, so there is a potential for this test to personalize the approach to prevention and allow a significant number of patients to avoid preventive medications, but we need further research to verify that routine use of this test is the best option for our patients,” said Miedema. While the study is significantly conclusive about use of CAC score in determining the efficacy of aspirin for heart patients, still more research needs to be done to verify the efficacy of aspirin to prevent primary heart attacks and stroke. 

The study was published in the May 2014 edition of Circulation: Cardiovascular Quality and Outcomes.